Macrogenics Inc [MGNX] stock prices are up 0.91% to $5.55 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MGNX shares have gain 12.80% over the last week, with a monthly amount glided 36.36%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Macrogenics Inc [NASDAQ: MGNX] stock has seen the most recent analyst activity on May 10, 2024, when TD Cowen downgraded its rating to a Hold. Previously, Stifel downgraded its rating to Hold on May 10, 2024, and dropped its price target to $7. On May 10, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $8 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $25 on April 26, 2024. TD Cowen upgraded its rating to a Buy. BTIG Research reiterated a Buy rating for this stock on March 04, 2024, and upped its price target to $24. In a note dated February 14, 2024, H.C. Wainwright downgraded an Neutral rating on this stock and boosted its target price from $12 to $14.
The stock price of Macrogenics Inc [MGNX] has been fluctuating between $3.14 and $21.88 over the past year. Currently, Wall Street analysts expect the stock to reach $15.43 within the next 12 months. Macrogenics Inc [NASDAQ: MGNX] shares were valued at $5.55 at the most recent close of the market. An investor can expect a potential return of 178.02% based on the average MGNX price forecast.
Analyzing the MGNX fundamentals
The Macrogenics Inc [NASDAQ:MGNX] reported sales of 43.36M for trailing twelve months, representing a drop of -62.83%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -4.23%, Pretax Profit Margin comes in at -0.54%, and Net Profit Margin reading is -0.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.15 and Total Capital is -0.95. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.41 points at the first support level, and at 5.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.73, and for the 2nd resistance point, it is at 5.91.
Ratios To Look Out For
It’s worth pointing out that Macrogenics Inc [NASDAQ:MGNX]’s Current Ratio is 3.63. As well, the Quick Ratio is 3.61, while the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 8.02, the price to book ratio is 3.27.
Transactions by insiders
Recent insider trading involved Peters Jeffrey Stuart, Senior VP and General Counsel, that happened on Apr 04 ’24 when 51395.0 shares were sold. Senior VP and General Counsel, Peters Jeffrey Stuart completed a deal on Mar 06 ’24 to sell 19625.0 shares. Meanwhile, Chief Operating Officer Risser Eric Blasius sold 41159.0 shares on Mar 04 ’24.
